

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

Rh36

RRID:CVCL_M599

Type: Cell Line

Proper Citation

RRID:CVCL_M599

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_M599

Proper Citation: RRID:CVCL_M599

Description: Cell line Rh36 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Embryonal rhabdomyosarcoma

Defining Citation: [PMID:10602515](#), [PMID:11051265](#), [PMID:12068308](#), [PMID:23882450](#), [PMID:26351324](#), [PMID:28196595](#), [PMID:31448612](#), [PMID:36768928](#)

Comments: Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Rh36

Synonyms: RH36, RH-36, Birch, BIRCH

Cross References: cancercelllines:CVCL_M599, Cell_Model_Passport:SIDM01350, Cosmic:724814, Cosmic:802042, DepMap:ACH-001751, GEO:GSM186453, GEO:GSM186454, GEO:GSM1676312, GEO:GSM1701646, PRIDE:PXD007755, PRIDE:PXD039480, Progenetix:CVCL_M599, Wikidata:Q54950343

ID: CVCL_M599

Record Creation Time: 20220427T221459+0000

Record Last Update: 20260905T182216+0000

Ratings and Alerts

No rating or validation information has been found for Rh36.

No alerts have been found for Rh36.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Larsen RK, et al. (2025) Non-cell-autonomous tumor promotion in DICER1 cancer predisposition. Developmental cell.

Oles AR, et al. (2025) MyoD is essential in rhabdomyosarcoma by promoting survival through differentiation and CYLD. iScience, 28(8), 113149.

Nguyen TDT, et al. (2023) Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time. Cancer research, 83(6), 939.

Savary C, et al. (2023) Fusion-negative rhabdomyosarcoma 3D organoids to predict effective drug combinations: A proof-of-concept on cell death inducers. Cell reports. Medicine, 4(12), 101339.

Hebron KE, et al. (2023) The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(2), 472.

McKay-Corkum GB, et al. (2023) Inhibition of NAD⁺-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(21), 4479.

Tombolan L, et al. (2022) Clinical significance of circulating tumor cells and cell-free DNA in pediatric rhabdomyosarcoma. Molecular oncology, 16(10), 2071.

Haydn T, et al. (2020) Next-generation sequencing reveals a novel role of lysine-specific demethylase 1 in adhesion of rhabdomyosarcoma cells. International journal of cancer, 146(12), 3435.